| Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia IM Bouligny, G Murray, M Doyel, T Patel, J Boron, V Tran, J Gor, Y Hang, ... EJHaem 4 (2), 381-392, 2023 | 4 | 2023 |
| The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine. M Doyel, IM Bouligny, G Murray, T Patel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19048-e19048, 2023 | 2 | 2023 |
| Mechanisms regulating the loss of Tregs in HUPO mice that develop spontaneous inflammatory arthritis QQ Huang, Y Hang, R Doyle, Q Mao, D Fang, RM Pope Iscience 26 (5), 2023 | 2 | 2023 |
| Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia IM Bouligny, G Murray, M Doyel, T Patel, J Boron, V Tran, J Gor, Y Hang, ... Medical Oncology 41 (3), 80, 2024 | 1 | 2024 |
| Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia IM Bouligny, G Murray, T Ho, M Doyel, T Patel, J Boron, V Tran, J Gor, ... Leukemia research 134, 107370, 2023 | 1 | 2023 |
| Immune Checkpoint Inhibitor Rechallenge in a Patient with Previous Fulminant Myocarditis SM Menachery, Y Hang, L Pritchard, A Poklepovic, W Bottinor The American Journal of Cardiology 199, 33-36, 2023 | 1 | 2023 |
| Clinical outcomes of core binding factor acute myeloid leukemia in the modern era. Y Hang, IM Bouligny, G Murray, T Patel, M Doyel, J Boron, V Tran, J Gor, ... Journal of Clinical Oncology 41 (16_suppl), e19054-e19054, 2023 | 1 | 2023 |
| IDH1/2mut for the win: comprehensive molecular stratification of venetoclax in combination with hypomethylating agents in AML IM Bouligny, G Murray, V Tran, J Gor, Y Hang, Y Alnimer, K Zacholski, ... Blood 140 (Supplement 1), 6335-6336, 2022 | 1 | 2022 |
| A Systematic Review of MRI Studies of the Cholinergic System in Lewy Body Diseases (P2-3.005) Y Hang, L Jin, C Tan, A Niaz, A Negida, M Barrett Neurology 102 (17_supplement_1), 2454, 2024 | | 2024 |
| Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia. K Zacholski, IM Bouligny, G Murray, T Patel, M Doyel, J Boron, V Tran, ... Journal of Clinical Oncology 41 (16_suppl), e19051-e19051, 2023 | | 2023 |
| Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia. G Murray, IM Bouligny, T Patel, M Doyel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19046-e19046, 2023 | | 2023 |
| IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia. G Murray, IM Bouligny, T Patel, M Doyel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19043-e19043, 2023 | | 2023 |
| FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia. V Tran, IM Bouligny, G Murray, T Patel, M Doyel, J Boron, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19047-e19047, 2023 | | 2023 |
| Social determinants of health as a primary driver in outcomes in acute myeloid leukemia: An urban academic center experience. IM Bouligny, G Murray, T Patel, M Doyel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e18659-e18659, 2023 | | 2023 |
| Treatment phase stratified outcomes of core binding factor acute myeloid leukemia. J Gor, IM Bouligny, G Murray, T Patel, M Doyel, J Boron, V Tran, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e19055-e19055, 2023 | | 2023 |
| Location-based cancer survival in Philadelphia chromosome-negative acute lymphoblastic leukemia: An urban center retrospective analysis. J Gor, IM Bouligny, V Tran, Y Hang, T Ho, K Zacholski, CM Venn, ... Journal of Clinical Oncology 41 (16_suppl), e18679-e18679, 2023 | | 2023 |
| Identification of predictive, treatment-specific Charlson comorbidity score thresholds in acute myeloid leukemia. IM Bouligny, G Murray, T Patel, M Doyel, J Boron, V Tran, J Gor, Y Hang, ... Journal of Clinical Oncology 41 (16_suppl), e18887-e18887, 2023 | | 2023 |
| Outcomes of Cancer Patients with COVID-19: The Virginia Commonwealth University Experience PJ Willard, Y Hang, T Olasehinde, N Bou Zeid, E Defor, ... Cancer Investigation 41 (5), 456-466, 2023 | | 2023 |
| Assessing the clinical utility of major indices for nonalcoholic fatty liver disease in East Asian populations Y Hang, C Lee, YM Roman Biomarkers in Medicine 17 (8), 445-454, 2023 | | 2023 |
| INCIDENCE OF ELEVATED/HYPERTENSIVE BLOOD PRESSURE AMONG YOUNG ADULTS PREVIOUSLY TREATED FOR CANCER E Miller, Y Hang, S Menachery, D Chuquin, X Deng, D Bandyopadhyay, ... Journal of the American College of Cardiology 81 (8_Supplement), 2218-2218, 2023 | | 2023 |
